Actionable news
All posts from Actionable news
Actionable news in CELG: Celgene Corporation,

Bristol-Myers/AbbVie's cancer med Empliciti approved in Europe

As expected, the European Commission approves Empliciti (elotuzumab), in combination with Celgene's (CELG -2.4%) Revlimid (lenalidomide) and dexamethasone, for the treatment of patients with multiple myeloma (MM) who have received at least one prior line of therapy. The approval follows a positive...